{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psychosis-schizophrenia/prescribing-information/interactions/","result":{"pageContext":{"chapter":{"id":"25b3e7d5-bc3d-5749-9304-a717c1f4e386","slug":"interactions","fullItemName":"Interactions","depth":2,"htmlHeader":"<!-- begin field a01e13a5-f3ab-4a31-939d-7e84b1e78b12 --><h2>Drug interactions</h2><!-- end field a01e13a5-f3ab-4a31-939d-7e84b1e78b12 -->","summary":"","htmlStringContent":"<!-- begin item f20da4c5-4d46-4493-81ba-4a49bdfff431 --><!-- begin field b9af2f8f-9044-4d27-9db1-c21982f84b15 --><ul><li><strong>The following interactions are common to all antipsychotics:</strong><ul><li><strong>Drugs with a sedative action </strong>(such as alcohol, analgesics, tricyclic antidepressants, and sedating antihistamines) will enhance the sedative effects of antipsychotics.</li><li><strong>Drugs with a hypotensive effect </strong>(for example antihypertensives) will enhance the hypotensive effect of antipsychotics.</li><li><strong>Drugs that prolong the QT interval, </strong>such as antiarrhythmics, macrolides (for example erythromycin), and tricyclic antidepressants, may have a synergistic effect. Avoid co-prescribing drugs that prolong the QT interval. These drugs are contraindicated with sertindole therapy.</li><li><strong>Diuretics </strong>may cause hypokalaemia, which may increase the risk of arrhythmias; monitor potassium levels in people taking diuretics.</li></ul></li><li><strong>Azole antifungals</strong><ul><li>Azole antifungals may increase levels of some antipsychotics, for example:<ul><li>Aripiprazole levels are predicted to be increased by itraconazole.</li><li>Haloperidol levels are increased by 30% or more by itraconazole.</li></ul></li><li>If azole antifungals are given concurrently with antipsychotics, monitor for signs of adverse effects of antipsychotics and consider reducing the dose as necessary.</li><li>The manufacturer of aripiprazole recommends halving the dose of aripiprazole if itraconazole is given concomitantly.</li></ul></li><li><strong>Carbamazepine</strong><ul><li>Carbamazepine reduces plasma levels of clozapine, haloperidol, and risperidone by half. Carbamazepine also reduces levels of aripiprazole, fluphenazine, olanzapine, quetiapine, and sertindole.<ul><li>Monitor the person's symptoms to ensure that antipsychotics remain effective.</li></ul></li><li>Carbamazepine levels are increased by haloperidol, quetiapine, or risperidone, or chlorpromazine with amoxapine.<ul><li>Monitor carbamazepine levels if these drugs are given together.</li></ul></li></ul></li><li><strong>Grapefruit juice</strong><ul><li>Advise the person not to drink grapefruit juice if they are taking pimozide. Grapefruit juice increases the levels of pimozide, possibly leading to torsades de pointes and potentially fatal arrhythmias.</li></ul></li><li><strong>Selective serotonin reuptake inhibitors (SSRIs)</strong><ul><li>SSRIs increase levels of some antipsychotics, for example:<ul><li>Haloperidol levels are increased by 20–30% by fluoxetine and by 20–60% by fluvoxamine.</li><li>Risperidone levels are increased by fluvoxamine, fluoxetine, and paroxetine.</li><li>Sertindole levels are increased two- to three-fold by fluoxetine and paroxetine.</li><li>Clozapine and olanzapine levels are increased by fluoxetine, fluvoxamine, paroxetine, sertraline, and possibly citalopram.</li></ul></li><li>Where antipsychotic drug levels are increased, the person should be monitored and the dose adjusted accordingly.</li></ul></li><li><strong>Smoking cessation</strong><ul><li>Smoking induces the metabolism of olanzapine and clozapine. If the person stops smoking, monitor for increased adverse effects and seek advice about dose adjustment if necessary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">MHRA, 2009a</a>].</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field b9af2f8f-9044-4d27-9db1-c21982f84b15 --><!-- end item f20da4c5-4d46-4493-81ba-4a49bdfff431 -->","topic":{"id":"9b90da89-2ffd-5b6a-9fc6-ea342404d5d8","topicId":"fd02ebc3-0f02-42b5-8737-e0608ca4330d","topicName":"Psychosis and schizophrenia","slug":"psychosis-schizophrenia","lastRevised":"Last revised in November 2020","chapters":[{"id":"d60310a0-752b-5399-8488-a567bf6a3925","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"10869ad6-510d-54db-bc6a-ce3618a1c478","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1025e31f-c89d-5344-b4ae-d5e8950a5c0e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"594160f5-1a9b-56f0-952c-5c400ea28785","slug":"changes","fullItemName":"Changes"},{"id":"e20c0ce8-30f6-5e09-81d1-3e6005f85efe","slug":"update","fullItemName":"Update"}]},{"id":"4c4f0990-85fa-5fc4-9a58-9f02a868a971","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02637a5f-4552-5e73-9245-cf480497e9a5","slug":"goals","fullItemName":"Goals"},{"id":"8c88de52-9655-52d8-b302-67641ae05beb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c6754da2-fd29-5d45-8097-40b8ec0589cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"31a210b8-403b-5530-b1ea-0b44a2595f07","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5630117-b04c-558a-b516-41c3eab9adbd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e9e078fd-a616-51bf-944f-2efbb2a01feb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"99d1cff5-adca-5573-9fa8-58c2e9f937e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23ac3781-557a-57b8-95b5-83db37a53fda","slug":"definition","fullItemName":"Definition"},{"id":"3e7238cc-23d8-56f6-a8af-255ed6a876d7","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"9576e7c9-3a1e-57d3-bb86-a4e5e10462e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b79b29b0-d7ad-5bad-87fd-e5a48ced5427","slug":"course-prognosis","fullItemName":"Course and prognosis"},{"id":"598444d7-6337-5133-a088-176b1f83ab01","slug":"complications","fullItemName":"Complications"}]},{"id":"a913b80f-eec4-5c47-9d9c-0b20f4648b73","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7897095-2be8-5df7-a7e3-c1060d4a453a","slug":"identifying-someone-at-risk-of-a-psychotic-disorder-or-experiencing-their-first-episode-of-psychosis","fullItemName":"Identifying someone at risk of a psychotic disorder or experiencing their first episode of psychosis"},{"id":"a8f36210-9cb6-590b-8e3d-7ddbc6d31e88","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f86ff69c-c33e-5b8c-affa-04759f25bf5a","fullItemName":"Management","slug":"management","subChapters":[{"id":"34c0807e-9463-536b-9ff4-c3537046a6ba","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"468f8b6f-bc79-5ecd-b1c2-d7ff27721abe","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"30f16f24-0127-53b7-bd08-c679a189090b","slug":"the-routine-schizophrenia-or-psychosis-review","fullItemName":"Scenario: The routine schizophrenia or psychosis review"},{"id":"c20919b9-2e4c-5c56-b3cd-7fb432199a8b","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"a9fe56bb-7ae3-5523-b0e2-5b7da5aa8439","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f78f8497-f98b-5445-82fe-23a4ced38576","slug":"available-antipsychotics","fullItemName":"Available antipsychotics"},{"id":"05e42d64-ee5a-5c2b-8817-5fc77abb19ec","slug":"adverse-effects","fullItemName":"Adverse effects"},{"id":"25b3e7d5-bc3d-5749-9304-a717c1f4e386","slug":"interactions","fullItemName":"Interactions"},{"id":"ed339043-f5e2-5209-9ba0-cb06890e1050","slug":"monitoring","fullItemName":"Monitoring"}]},{"id":"7ae82132-000d-507c-b73d-542c43656041","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1bf0a6af-76cf-5f6b-b7fb-4c746ff0f413","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"49b46ed4-7209-5c01-b07f-54117f9ad3c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4647644-8726-5bfc-b471-6e157c3f10a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a31ae673-4520-58d5-95ee-db2395fb5238","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3beebe4c-a826-5b46-a8cd-a97fe8ec3b8b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"aaaadecf-036b-531f-a8bf-75fccd84219f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49078833-deae-54f3-ad89-562370e4d181","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a9fe56bb-7ae3-5523-b0e2-5b7da5aa8439","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}